Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Enterolactone is differently associated with estrogen receptor beta-negative and -positive breast cancer in a Swedish nested case-control study

In English

Författare

Summary, in English

BACKGROUND: Differences in the estrogen receptor (ER) status of tumors may explain ambiguities in epidemiologic studies between the blood concentrations of enterolactone and breast cancer. To our knowledge, the association between enterolactone and ERbeta-defined breast cancer has previously not been examined.

METHODS: A nested case-control study within the Malmö Diet and Cancer cohort used 366 cases and 733 matched controls to identify the major determinants of plasma enterolactone and to examine the association between enterolactone concentration and breast cancer risk and if this association differs depending on the ERalpha and ERbeta status of tumors. A modified diet history method assessed dietary habits. Time-resolved fluoroimmunoassay determined enterolactone concentrations and immunohistochemistry using tissue microarray determined ER status.

RESULTS: Dietary fiber, as well as fruits and berries, and high-fiber bread showed statistically significant correlations with enterolactone (r, 0.13-0.22). Smoking and obesity were associated with lower enterolactone concentrations. Enterolactone concentrations above the median (16 nmol/L) were associated with reduced breast cancer risk when compared with those below [odds ratio, 0.75; 95% confidence interval (95% CI), 0.58-0.98]. The reduced risk was only observed for ERalpha [positive (+); odds ratio, 0.73; 95% CI, 0.55-0.97] and ERbeta [negative (-)] tumors (odds ratio, 0.60; 95% CI, 0.42-0.84), with significantly different risks for ERbeta (-) and ERbeta (+) tumors (P for heterogeneity = 0.04).

CONCLUSIONS: This study supports the suggestion that enterolactone is a biomarker of a healthy lifestyle. The protective association between enterolactone and breast cancer was significantly different between ERbeta (-) and ERbeta (+) tumors and most evident in tumors that express ERalpha but not ERbeta.

Publiceringsår

2008-11

Språk

Engelska

Sidor

51-3241

Publikation/Tidskrift/Serie

Cancer Epidemiology Biomarkers & Prevention

Volym

17

Issue

11

Dokumenttyp

Artikel i tidskrift

Förlag

American Association for Cancer Research

Ämne

  • Cancer and Oncology

Nyckelord

  • 4-Butyrolactone
  • Adult
  • Aged
  • Biomarkers, Tumor
  • Breast Neoplasms
  • Case-Control Studies
  • Diet
  • Estrogen Receptor alpha
  • Estrogen Receptor beta
  • Female
  • Humans
  • Lignans
  • Linear Models
  • Microarray Analysis
  • Middle Aged
  • Obesity
  • Prospective Studies
  • Reproducibility of Results
  • Risk Assessment
  • Smoking
  • Surveys and Questionnaires
  • Sweden

Status

Published

Forskningsgrupp

  • Nutrition Epidemiology
  • Diabetes - Cardiovascular Disease
  • Lund Melanoma Study Group
  • Pathology, Malmö

ISBN/ISSN/Övrigt

  • ISSN: 1538-7755